Gene therapy is delivered through viral vectors — AAV, lentiviral, and adenoviral being the three dominant platforms. AAV dominates in vivo systemic delivery (rare disease, ophthalmology, neurology); lentivirus is the workhorse for ex vivo cell engineering including CAR-T; adenoviral vectors remain relevant for vaccines and select gene therapy programs. Most gene therapy CDMOs specialize in one or two vector platforms, and platform experience is the first filter in any sponsor's shortlist.
The ranking below aggregates every CDMO tracked as a gene therapy manufacturer across these platforms. For platform-specific rankings, use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors evaluating end-to-end programs that combine vector manufacturing with downstream cell processing, the <a href="/modality/cell-and-gene-therapy">cell and gene therapy view</a> extends this list with cell therapy CDMOs.
FDA inspection outcomes across these CDMOs: 1 NAI (no action), 2 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (3).
Last updated 2026-08-27. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform.
Regulatory record on-platform
A CDMO with a strong FDA record on AAV manufacturing doesn't automatically de-risk lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use.
Capacity match to phase
Early clinical AAV runs at 50-200L; commercial can reach 1000-2000L single-batch. Lentiviral commercial supply is a much narrower field. Confirm the CDMO's capacity headroom at your target phase before shortlisting.
Analytics maturity
Vector analytics — capsid ratio, titer, potency, RCL for lentivirus — drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
How do Indian CDMOs compare to Chinese and Korean alternatives on regulatory posture?
Indian CDMOs have historically led Asian peers in FDA inspection density — the FDA maintains a large inspection presence in India and Indian pharmaceutical exports to the US are among the highest globally. That translates to Indian CDMOs typically holding more FDA inspections on record than Chinese or Korean counterparts of comparable size. That said, inspection density is not the same as inspection outcome — the Signal Score's Quality Compliance pillar weights the classification (NAI/VAI/OAI), not just the count. Sponsors comparing Asian CDMOs should focus on the specific facility's inspection outcome record, not the country-aggregate; individual profile pages surface facility-level detail.
Which Indian CDMOs handle biologics and advanced therapy modalities?
India's CDMO base has traditionally been strongest in small molecules and oral solid dosage forms, but the biologics and advanced-therapy footprint has grown substantially. Notable capabilities exist across mAb manufacturing, biosimilar production, and increasingly viral vector + cell therapy. Cross-reference with modality pages to filter Indian CDMOs by capability class: biologics, mRNA, cell therapy, or the gene therapy umbrella. Individual CDMO profile pages surface the specific modality capabilities on file.
US and EU regulatory considerations for India-manufactured drug supply
Indian CDMOs supplying US markets need active FDA registrations and pre-approval inspection posture; the FDA has been publicly focused on Indian generic pharmaceutical quality for years, and inspection outcomes there materially affect commercial supply eligibility. EU supply requires EMA GMP certification with an EU-based Qualified Person for batch release, which for Indian-manufactured material requires either an EU-based CDMO partner for release or an in-house EU QP arrangement. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Indian CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.
Gene Therapy CDMOs — Frequently Asked Questions
Who are the top Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Gene Therapy CDMOs include Genezen, Indiana University Vector Production Facility. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 1 Gene Therapy CDMO with FDA inspection records and 0 EMA/MHRA GMP certificates across the group.
What should I look for in a gene therapy CDMO?
Match the vector platform to your program first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, analytics maturity for that vector type, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific detail.
How many gene therapy CDMOs does CDMO Signal track?
63 CDMOs are tracked as gene therapy manufacturers — the union of AAV, lentiviral, adenoviral, and generally-tagged gene therapy CDMOs. Each is scored independently on the standard four-pillar Signal Score composite.